Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study

Author:

Mohri Takako1ORCID,Okamoto Sawako23ORCID,Nishioka Yuichi2ORCID,Myojin Tomoya2ORCID,Kubo Shinichiro2,Higashino Tsuneyuki4,Okada Sadanori1ORCID,Akai Yasuhiro5ORCID,Noda Tatsuya2ORCID,Ishii Hitoshi6ORCID,Imamura Tomoaki2ORCID

Affiliation:

1. Department of Diabetes and Endocrinology, Nara Medical University Hospital, Nara 634-8522, Japan

2. Department of Public Health, Health Management and Policy, Nara Medical University, Nara 634-8521, Japan

3. Education Development Center, Nara Medical University, Nara 634-8521, Japan

4. Healthcare and Wellness Division, Mitsubishi Research Institute Inc., Tokyo 100-8141, Japan

5. Department of Community-Based Medicine, Nara Medical University, Nara 634-8521, Japan

6. Department of Doctor-Patient Relationships, Nara Medical University, Nara 634-8521, Japan

Abstract

Patient data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) are used to assess the effect of biguanide administration on rates of lactic acidosis (LA) in hospitalized diabetes mellitus (DM) patients. In this retrospective cohort study (from April 2013 to March 2016), we compare DM inpatients prescribed biguanides to DM inpatients who were not prescribed biguanides to quantify the association between biguanides and incidence of LA. In total, 8,111,848 DM patient records are retrieved from the NDB. Of the 528,768 inpatients prescribed biguanides, 782 develop LA. Of the 1,967,982 inpatients not prescribed biguanides, 1310 develop LA. The rate ratio of inpatients who develop LA and are administered biguanides to those who developed LA without receiving biguanides is 1.44 (95% CI, 1.32–1.58). Incidence rates and rate ratios for both sexes are elevated in the group prescribed biguanides for patients aged 70 years and older, markedly in those 80 years and older: 40.12 and 6.31 (95% CI, 4.75–8.39), respectively, for men and 34.96 and 5.40 (95% CI, 3.91–7.46), respectively, for women. Biguanides should be used conservatively in patients older than 70 years, particularly for those with comorbidities, and with caution in patients 80 years and older.

Funder

Japan Agency for Medical Research and Development

Health Science and Labor Research Grants

Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3